Bros. Advisors Lp Baker Purchases 807,338 Shares of Immunocore Holdings plc (NASDAQ:IMCR) Stock

Immunocore Holdings plc (NASDAQ:IMCR) Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Immunocore Stock Performance

Shares of IMCR opened at $30.43 on Friday. The company has a market capitalization of $1.52 billion, a PE ratio of -32.03 and a beta of 0.79. Immunocore Holdings plc has a one year low of $27.19 and a one year high of $66.00. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The company’s fifty day moving average price is $30.00 and its 200 day moving average price is $31.20.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IMCR. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Wednesday, March 12th. Morgan Stanley reissued an “equal weight” rating and set a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $71.00 target price on shares of Immunocore in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $65.64.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Primecap Management Co. CA raised its holdings in Immunocore by 26.7% in the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after acquiring an additional 520,950 shares during the period. State Street Corp raised its holdings in Immunocore by 63.9% in the 3rd quarter. State Street Corp now owns 76,671 shares of the company’s stock worth $2,387,000 after acquiring an additional 29,897 shares during the period. Principal Financial Group Inc. raised its holdings in Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after acquiring an additional 109,206 shares during the period. Hennion & Walsh Asset Management Inc. raised its holdings in Immunocore by 125.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock worth $1,463,000 after acquiring an additional 27,598 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Immunocore by 7,437.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock worth $2,872,000 after acquiring an additional 91,033 shares during the period. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.